OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook
OneMedNet Corp (ONMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook MINNEAPOLIS, NOVEMBER 6, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provi
How this was made
The 30-second read
Why it matters
The guidance signals rapid scaling of the company's AI‑driven real‑world data platform.
Market read
Guidance may attract investors seeking exposure to health‑data AI services.
What to watch
Potential delays in customer data acceptance could compress Q4 results
OneMedNet preliminarily reports approximately $1 million of Q3 2026 revenue and guides Q4 2026 revenue to $12 million to $14 million
The release gives only a preliminary revenue figure for Q3 2026 and a Q4 2026 revenue range. It prints no gross margin, operating expense, net income, EPS, cash flow or balance sheet figures. The Q4 range depends on customer acceptance of delivered data, and the Q3 figure is subject to adjustment in the 10-Q. The stated sequential and year-over-year growth is large, but the dollar bases for those comparisons are not printed.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, Q3 2026 (quarter ended September 30, 2026, preliminary)other | approximately $1 million | 242% increase | 465% increase |
Q4 2026 outlook
- Revenueapproximately $12 million to $14 million
- NoteGuidance is pending anticipated customer acceptance of delivered data by quarter-end.
- NoteThe Company states that 2026 revenue is weighted to occur at a faster pace in the fourth quarter of 2026.
What drove it
- The Company states that its sales funnel grew substantially over 2026 and that it began delivering on that funnel at scale in Q3 2026.
- The Company states that its Q4 2026 revenue pace reflects data coming direct from its healthcare provider partners and the build-out of its de-identification pipeline and delivery infrastructure to scale with demand.
- The Company states that Q3 2026 revenue of approximately $1 million is consistent with previously communicated delivery timing.
Concerns
- Q3 2026 revenue is preliminary and subject to finalization and adjustment in the Form 10-Q.
- The Q4 2026 revenue range is pending anticipated customer acceptance of delivered data by quarter-end.
- The Company states that 2026 revenue is weighted to the fourth quarter, which concentrates the expected revenue in one period.
- The release carries forward-looking risk factors, including the timing of customer acceptance and data delivery, the competitive environment, and the ability to keep pace with new technology and changing market needs.
What to watch
- The Form 10-Q for the quarter ended September 30, 2026, which the Company expects to release by November 16, 2026, and whether the final Q3 revenue differs from approximately $1 million.
- Customer acceptance of delivered data by the end of Q4 2026, which the Q4 revenue guidance depends on.
- Whether Q4 2026 revenue lands within the $12 million to $14 million range.
- Full financial statements for the period, including gross margin, operating expenses, net loss, cash and cash flow, none of which are printed in this release.
Analysis
OneMedNet's release is a preliminary revenue update rather than a full results release. The Company states that Q3 2026 revenue is approximately $1 million for the quarter ended September 30, 2026. It describes this as a 242% increase from the quarter ended June 30, 2026 and a 465% increase from the quarter ended September 30, 2025. The dollar amounts behind those two percentage changes are not printed in the filing, so the prior-quarter and prior-year revenue figures cannot be stated from the document.
The Company also guides Q4 2026 revenue to approximately $12 million to $14 million. It ties that range to customer acceptance of delivered data by quarter-end and says that 2026 revenue is weighted to a faster pace in the fourth quarter. Management attributes the expected Q4 pace to data coming directly from its healthcare provider partners and to the build-out of its de-identification pipeline and delivery infrastructure. The Q4 range therefore rests on two conditions the filing names: customer acceptance and delivery at scale.
The filing does not print gross margin, operating expenses, net income or loss, EPS, operating or free cash flow, cash, debt, total assets or equity. Without those lines, the read on profitability, cost structure and liquidity cannot be made from this document. The release also contains no segment or geographic revenue breakdown.
The Company describes the Q3 figure as subject to finalization and adjustment in its Form 10-Q, which it expects to release by November 16, 2026. Investors will need that filing to confirm the Q3 revenue and to see the full financial statements. Management's CEO quote states that the sales funnel has grown and that delivery has begun, but the release provides no backlog, order value or customer count to measure that funnel.
No prior-period outlook is provided, so no comparison of results against earlier guidance is made here. Overall the release shows a sharp step-up in revenue and a forward range that is large relative to the Q3 figure, with the Q4 outcome dependent on customer acceptance that has not yet occurred.
Management, verbatim
Our sales funnel has grown substantially this year, and we are now delivering on it,
Aaron Green, President & CEO
The hardest work in this business; curating, de-identifying, and delivering regulatory-grade multimodal data at scale, is substantially complete.
Aaron Green, President & CEO
Not in the filing
stated, not guessed- Dollar revenue for the quarter ended September 30, 2025 (prior-year quarter), needed to compute the 465% change
- Dollar revenue for the quarter ended June 30, 2026 (prior quarter), needed to compute the 242% change
- Gross margin or cost of revenue for Q3 2026
- Operating expenses, operating income or loss for Q3 2026
- Net income or loss and GAAP or non-GAAP EPS for Q3 2026
- Operating cash flow, free cash flow, cash and cash equivalents, debt, total assets and equity
- Full-year 2026 revenue or other full-year guidance figures (only Q4 2026 revenue is guided)
- Gross margin, operating expense, tax rate and other guidance figures for Q4 2026
- Prior-period outlook, so that no guidance comparison can be made
- Segment or geographic revenue breakdown
- Backlog, order value, or customer count underlying the sales funnel
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
OneMedNet filed an 8‑K reporting preliminary Q3 revenue and Q4 outlook.
Ticker impact
issued guidance of approximately $1 million Q3 revenue and $12‑14 million Q4 outlook
potential upside as investors price in higher revenue expectations
The company reports a 242% increase from the prior quarter and a 465% jump year‑over‑year, indicating accelerating demand for its data platform
Market effects
May boost sentiment for real‑world data and health‑tech providers
Limited to U.S. biotech and data‑service investors
Minimal
Counterpoint
Revenue guidance remains modest in absolute terms; growth may be unsustainable
Key entities
- companyOneMedNet Corp
Provider of regulatory‑grade real‑world data
